- ►diabetesjournals.org G Viberti, SE Kahn, DA Greene, WH Herman, B … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A Diabetes Outcome Progression Trial (ADOPT) is a randomized,
double-blind, parallel-group study consisting of a screening visit, a 4-week placebo run-in, a
4-year treatment period, and an ... Cited by 168 - Related articles - BL Direct - All 14 versions
- ►endojournals.org HE Lebovitz, JF Dole, R Patwardhan, EB … - Journal of Clinical …, 2001 - Endocrine Soc This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type 2
diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized to
receive rosiglitazone [2 or 4 mg ... Cited by 415 - Related articles - BL Direct - All 5 versions
- ►endojournals.org SA Smith, LE Porter, N Biswas, MI Freed - Journal of Clinical …, 2004 - Endocrine Soc An elevation in the ratio of proinsulin (PI) to immunoreactive insulin (IRI) is inversely related to
ß-cell function in type 2 diabetes, and increased PI is an independent risk factor for coronary
heart disease. An objective of the ... Cited by 38 - Related articles - All 5 versions
- ►zhaoys.com [PDF] V Fonseca, J Rosenstock, R Patwardhan, A Salzman - Jama, 2000 - Am Med Assoc Context Most antidiabetic agents target only 1 of several underlying causes of diabetes. The
complementary actions of the antidiabetic agents metformin hydrochloride and rosiglitazone maleate
may maintain optimal glycemic ... Cited by 520 - Related articles - BL Direct - All 8 versions
- ►diabetesjournals.org HE Lebovitz, M Kreider, MI Freed - Diabetes Care, 2002 - Am Diabetes Assoc OBJECTIVE—Troglitazone treatment has been associated with idiosyncratic hepatic reaction leading
to hepatic failure and death in some patients. This raises questions regarding whether all
thiazolidinediones or peroxisomal ... Cited by 150 - Related articles - BL Direct - All 8 versions
HC Gerstein, S Yusuf, R Holman, J Bosch, J Pogue - Diabetologia, 2004 - ncbi.nlm.nih.gov AIMS/HYPOTHESIS: Diabetes is a rapidly rising independent risk factor for atherosclerosis and
serious illness. This risk can be reduced by lifestyle changes and/or various drugs. Novel therapies
to prevent diabetes, as well as new ... Cited by 71 - Related articles
- ►infodiabetes.it [PDF] PD Home, SJ Pocock, H Beck-Nielsen, R Gomis, M … - Diabetologia, 2005 - Springer Page 1. Diabetologia (2005) 48: 1726–1735 DOI 10.1007/s00125-005-1869-1 ARTICLE PD Home . SJ
Pocock . H. Beck-Nielsen . R. Gomis . M. Hanefeld . H. Dargie . M. Komajda . J. Gubb . N. Biswas .
NP Jones Rosiglitazone Evaluated for Cardiac Outcomes and Regulation ... Cited by 147 - Related articles - BL Direct - All 5 versions
MI Freed, R Ratner, SM Marcovina, MM Kreider, N … - The American journal of …, 2002 - Elsevier This study evaluated the effects of rosiglitazone therapy on lipids and the efficacy and safety of
rosiglitazone in combination with atorvastatin in patients with type 2 diabetes mellitus.
Three-hundred thirty-two patients ... Cited by 170 - Related articles - All 5 versions
